Raymond James Financial
MGX icon

Raymond James Financial’s Metagenomi Therapeutics MGX Stock Holding History

Raymond James Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157
Closed -$232 – 6856
2025
Q2 		$232 Buy
+157
New +$246 ﹤0.01% 6766

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raymond James Financial's MGX Position: Q3 2025 in Review

Raymond James Financial sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 157 shares — an estimated $232 sold.

Raymond James Financial first reported a position in MGX in Q2 2025 and held it in 1 quarter. The position peaked at $232 in Q2 2025. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Raymond James Financial reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 157 Metagenomi Therapeutics shares in Q3 2025, an estimated $232.
  • Raymond James Financial first reported a position in Metagenomi Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Metagenomi Therapeutics position peaked at $232 in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.